The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients.

BRONJ MRONJ ONJ bisphosphonates myeloma osteonecrosis

Journal

Dentistry journal
ISSN: 2304-6767
Titre abrégé: Dent J (Basel)
Pays: Switzerland
ID NLM: 101716125

Informations de publication

Date de publication:
20 Jan 2021
Historique:
received: 18 11 2020
revised: 24 12 2020
accepted: 14 01 2021
entrez: 27 1 2021
pubmed: 28 1 2021
medline: 28 1 2021
Statut: epublish

Résumé

(1) Background: Multiple myeloma is a rare cancer that primarily affects the bone marrow. Osteoclasts are responsible for increased bone resorption and, therefore, bone destruction. Bisphosphonates are a class of drugs that can slow down bone resorption by reducing the number and action of osteoclasts. Intravenous injections of bisphosphonates (generally Zoledronic Acid) are administered to patients affected by Multiple Myeloma, but BRONJ is described as a serious side effect. This 5-year retrospective study aims to evaluate the efficacy of appropriate dental treatment protocols prior to initiating bisphosphonate therapy to prevent the development of BRONJ. (2) Methods: A total of 99 patients with symptomatic multiple myeloma were involved in this study (41-90 years, mean age 65 years, standard deviation 5 years). The data relating to the visits were tracked using a specific server and consulting the clinical reports. The AAOMS (American Association of Oral and Maxillofacial Surgeons) position was applied for both diagnosis and treatment. A total of 79 patients were examined before the administration of bisphosphonates (group A) and 20 after (group B). (3) Results: The entire sample required dental treatment: 23.2% underwent restorative therapy, 8% endodontic treatments, 44.4% tooth extractions. Periodontal disease was present in 41.4% of the patients. No osteonecrosis was observed in the first group, whereas BRONJ was found in five patients of the second one (25%) and two patients (10%) showed osteosclerotic areas under investigation [OR 0.026 (CI 0.0027 to 0.2454)]. (4) Conclusions: In the literature, there are no precise data about the prevalence of BRONJ. Despite the limitation of the present study, we point out that dental treatment before the treatment with intravenous bisphosphonates can help in reducing the incidence of BRONJ and good dental status is necessary for BRONJ prevention.

Identifiants

pubmed: 33498207
pii: dj9020011
doi: 10.3390/dj9020011
pmc: PMC7908966
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Clin Oncol. 2006 Feb 20;24(6):945-52
pubmed: 16484704
Crit Rev Oncol Hematol. 2007 May;62(2):148-52
pubmed: 17336086
Ann Diagn Pathol. 2002 Apr;6(2):129-40
pubmed: 12004363
Ann Oncol. 2009 Aug;20(8):1303-17
pubmed: 19465418
J Immunol. 1987 Mar 1;138(5):1464-8
pubmed: 3492553
Cochrane Database Syst Rev. 2012 May 16;(5):CD003188
pubmed: 22592688
Ann Oncol. 2009 Jan;20(1):117-20
pubmed: 18689864
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):61-70
pubmed: 19371816
J Clin Periodontol. 2005;32 Suppl 6:132-58
pubmed: 16128835
Am J Hematol. 2011 Jan;86(1):57-65
pubmed: 21181954
Ann Intern Med. 2006 May 16;144(10):753-61
pubmed: 16702591
J Oral Maxillofac Surg. 2007 Mar;65(3):415-23
pubmed: 17307586
J Clin Periodontol. 2005 Nov;32(11):1123-8
pubmed: 16212571
Int J Clin Exp Med. 2015 May 15;8(5):6743-54
pubmed: 26221212
J Clin Oncol. 2009 Nov 10;27(32):5356-62
pubmed: 19805682
Oncologist. 2011;16(5):651-62
pubmed: 21493759
J Clin Oncol. 2011 Jun 10;29(17):e521-2; author reply e523-4
pubmed: 21537047
J Oral Maxillofac Surg. 2010 May;68(5):1179-82
pubmed: 20185222
J Stomatol Oral Maxillofac Surg. 2020 Aug 20;:
pubmed: 32827811
Anticancer Res. 2013 Sep;33(9):3917-24
pubmed: 24023329
Lancet. 2010 Dec 11;376(9757):1989-99
pubmed: 21131037
Laryngoscope. 1997 Jun;107(6):741-6
pubmed: 9185729
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):71-4
pubmed: 19371817
Oral Oncol. 2008 Sep;44(9):857-69
pubmed: 18282788
Biomed Res Int. 2018 Sep 16;2018:2684924
pubmed: 30306086
Lancet. 2009 Jul 25;374(9686):324-39
pubmed: 19541364
Support Care Cancer. 2014 Jan;22(1):259-67
pubmed: 24048519
Cureus. 2020 Feb 10;12(2):e6944
pubmed: 32190495
J Clin Oncol. 2005 Dec 1;23(34):8580-7
pubmed: 16314620
N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102
pubmed: 16000365

Auteurs

Christian Bacci (C)

Clinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy.

Alessia Cerrato (A)

Clinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy.

Virginia Dotto (V)

Clinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy.

Renato Zambello (R)

Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy.

Gregorio Barilà (G)

Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy.

Albana Liço (A)

Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy.

Gianpietro Semenzato (G)

Department of Medicine, Hematology and Clinical Immunology Section, University of Padova, 35128 Padova, Italy.

Edoardo Stellini (E)

Clinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy.

Gastone Zanette (G)

Clinical Dentistry Department of Neurosciences Via Giustiniani 1, University of Padova, 35128 Padova, Italy.

Classifications MeSH